Infinity Pharmaceuticals Given New $22.00 Price Target at Goldman Sachs Group Inc. (INFI)
Goldman Sachs Group Inc. upped their target price on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $20.00 to $22.00 in a research note issued on Wednesday, Analyst Ratings Network.com reports. Goldman Sachs Group Inc.’s price objective would suggest a potential upside of 8.59% from the stock’s previous close.
Infinity Pharmaceuticals (NASDAQ:INFI) traded down 2.22% on Wednesday, hitting $20.26. The stock had a trading volume of 609,580 shares. Infinity Pharmaceuticals has a 52-week low of $15.45 and a 52-week high of $50.51. The stock has a 50-day moving average of $20.01 and a 200-day moving average of $28.4. The company’s market cap is $972.1 million.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its earnings results on Thursday, August 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.06. During the same quarter last year, the company posted ($0.54) earnings per share. Analysts expect that Infinity Pharmaceuticals will post $-2.90 EPS for the current fiscal year.
Separately, analysts at Morgan Stanley cut their price target on shares of Infinity Pharmaceuticals (NASDAQ:INFI) from $47.00 to $25.00 in a research note to investors on Monday, August 19th. They now have a “hold” rating on the stock.
Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $33.86.
In other Infinity Pharmaceuticals news, CEO Adelene Perkins sold 45,000 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $20.72, for a total value of $932,400.00. Following the transaction, the chief executive officer now directly owns 447,535 shares of the company’s stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.